Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Keita MIURA"'
Autor:
Keita Miura, Takehito Shukuya, Naoki Furuya, Ryo Morita, Akira Kisohara, Atsuto Mouri, Satoshi Watanabe, Hisashi Tanaka, Aya Hirata, Taiki Hakozaki, Kosuke Hamai, Naoko Matsumoto, Kana Watanabe, Hironori Ashinuma, Eisaku Miyauchi, Koji Sugano, Shinobu Hosokawa, Koji Amano, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemonodo, Kazuhisa Takahashi
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 6, Pp 2618-2628 (2024)
ABSTRACT Background Cancer cachexia complicates advanced non‐small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first‐line systemic therapy. Me
Externí odkaz:
https://doaj.org/article/2bd96d96f73f40fa8b85b8d8ecdb6499
Autor:
Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Haruyasu Murakami, Hirotsugu Kenmotsu, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1831-1841 (2024)
Abstract Background Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemothera
Externí odkaz:
https://doaj.org/article/1c619e4840f7419cb18ab6e638421ba1
Autor:
Meiko Morita, Akira Ono, Motoki Sekikawa, Kosei Doshita, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Mitsuhiro Isaka, Yasuhisa Ohde, Toshiaki Takahashi
Publikováno v:
Cancer Reports, Vol 7, Iss 9, Pp n/a-n/a (2024)
ABSTRACT Background Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable gene alterations in non‐small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who undergo surgical resection for non
Externí odkaz:
https://doaj.org/article/3c7205c59c0848928a7fc40d19564462
Autor:
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and pr
Externí odkaz:
https://doaj.org/article/2b814dbbea994c51a018f1a190fff4f2
Autor:
Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe, Hiroaki Kodama, Keita Miura, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 6, Pp 477-485 (2024)
Abstract Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohis
Externí odkaz:
https://doaj.org/article/e463e71dc180423c8cb17938224f6040
Autor:
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 35, Pp 3475-3482 (2023)
Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and
Externí odkaz:
https://doaj.org/article/4fa201b940bf4f3497e40475cb88b5de
Autor:
Yuichiro Nishibori, Hirotsugu Kenmotsu, Kenju Ando, Ayumi Tonsho, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Noboru Morikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Hideyuki Harada, Toshiaki Takahashi
Publikováno v:
Cancer Treatment and Research Communications, Vol 41, Iss , Pp 100849- (2024)
Objectives: The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding
Externí odkaz:
https://doaj.org/article/10a0f9b6834e4795925cd6a167840c00
Autor:
Daisuke Hazama, MD, PhD, Kenji Nakahama, MD, PhD, Hiroaki Kodama, MD, Akito Miyazaki, MD, Koichi Azuma, MD, PhD, Yosuke Kawashima, MD, Yuki Sato, MD, Kentaro Ito, MD, Yoshimasa Shiraishi, MD, Keita Miura, MD, Takayuki Takahama, MD, PhD, Satoshi Oizumi, MD, PhD, Yoshinobu Namba, MD, Satoshi Ikeda, MD, PhD, Hiroshige Yoshioka, MD, PhD, Asuka Tsuya, MD, PhD, Yuichiro Yasuda, MD, PhD, Yoshiki Negi, MD, PhD, Ayako Hara, MD, Michihito Toda, MD, PhD, Motoko Tachihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100613- (2024)
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were foun
Externí odkaz:
https://doaj.org/article/ceb8623f26cd4608b0d8ffd019ba6537
Autor:
Takehito Shukuya, Kazuhisa Takahashi, Yasushi Shintani, Keita Miura, Ikuo Sekine, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Tomoya Kawaguchi, Nobuyuki Yamamoto, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 3, Pp 1274-1285 (2023)
Abstract Background Cancer cachexia is a syndrome that does not fully recover with nutritional support and causes appetite loss and body weight loss. It worsens a patient's quality of life and prognosis. In this study, the epidemiology of cachexia in
Externí odkaz:
https://doaj.org/article/68660320fdbd4d5392bc951bfce4c97d
Autor:
Kana Kurokawa, Yoichiro Mitsuishi, Naoko Shimada, Naoaki Ito, Misa Ogiwara, Keita Miura, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Rina Shibayama, Hiromasa Goto, Kazuhisa Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 5, Pp 442-449 (2023)
Abstract Background and Aim Immune checkpoint inhibitors have significantly improved the clinical outcomes of many cancer types, but they induce a range of immune‐related adverse events (irAEs). Although adrenal insufficiency (AI) is a rare irAE, i
Externí odkaz:
https://doaj.org/article/e243eed5e31e4d2c83f5d4e095335150